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Abstract. 
 
Hypertrophy is a basic cellular response to a
variety of stressors and growth factors, and has been
best characterized in myocytes. Pathologic hypertrophy
of cardiac myocytes leads to heart failure, a major cause
of death and disability in the developed world. Several
cytosolic signaling pathways have been identiﬁed that
transduce prohypertrophic signals, but to date, little
work has focused on signaling pathways that might neg-
atively regulate hypertrophy. Herein, we report that
 
glycogen synthase kinase-3
 
b
 
 (GSK-3
 
b
 
), a protein ki-
nase previously implicated in processes as diverse as
development and tumorigenesis, is inactivated by hy-
 
pertrophic stimuli via a phosphoinositide 3-kinase–
dependent protein kinase that phosphorylates GSK-3
 
b
 
on ser 9. Using adenovirus-mediated gene transfer of
GSK-3
 
b
 
 containing a ser 9 to alanine mutation, which
prevents inactivation by hypertrophic stimuli, we dem-
onstrate that inactivation of GSK-3
 
b
 
 is required for
cardiomyocytes to undergo hypertrophy. Furthermore,
our data suggest that GSK-3
 
b
 
 regulates the hyper-
trophic response, at least in part, by modulating the nu-
clear/cytoplasmic partitioning of a member of the nu-
clear factor of activated T cells family of transcription
factors. The identiﬁcation of GSK-3
 
b
 
 as a transducer of
antihypertrophic signals suggests that novel therapeutic
strategies to treat hypertrophic diseases of the heart
could be designed that target components of the GSK-3
pathway.
Key words: heart • nuclear factor of activated T cells
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Introduction
 
Many pathologic stimuli induce the heart to undergo adap-
tive hypertrophic growth that temporarily augments car-
diac function. Although the initial hypertrophic response
may be beneficial, sustained hypertrophy often undergoes
a transition to heart failure, which is a leading cause of
mortality and morbidity worldwide, and is characterized
by a progressive deterioration in cardiac function. Inten-
sive investigation over the last several years has led to the
identification of intracellular signaling pathways that are
believed to transduce prohypertrophic signals. However,
the nature of the cross-talk between these pathways re-
mains unclear and, more importantly, negative regulators
of the hypertrophic response have not been identified.
Glycogen synthase kinase-3 (GSK-3)
 
1
 
 is a highly con-
served protein kinase that is believed to play a critical role
in development as a component of the Wnt/wingless path-
way, and in a number of human disease states including tu-
morigenesis, diabetes, and Alzheimer’s disease (Parker et
al., 1983; Siegfried et al., 1992; Welsh and Proud, 1993; He
et al., 1995; Korinek et al., 1997; Morin et al., 1997; Rubin-
feld et al., 1997). Unlike most protein kinases, GSK-3 is
active in the unstimulated cell and becomes inactivated
when cells are stimulated by a variety of mitogens or by
the Wnt/wingless pathway (Woodgett, 1994).
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Abbreviations used in this paper:
 
 ANF, atrial natriuretic factor; ET-1, en-
dothelin-1; GFP, green fluorescent protein; GSK-3, glycogen synthase ki-
nase-3; IGF-1, insulin-like growth factor-1; ILK, integrin-linked kinase;
MOI, multiplicity of infection; NF-AT, nuclear factor of activated T cells;
PE, phenylephrine; PI3-K, phosphoinositide 3-kinase; PKB, protein ki-
nase B; SAPK, stress-activated protein kinase. 
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Many of the targets of GSK-3 that have been identified
to date, including c-Jun, cyclin D1, several metabolic en-
zymes, 
 
b
 
-catenin, and at least two nuclear factors of acti-
vated T cells (NF-ATs), are repressed by the action of
GSK-3, and inactivation of GSK-3 relieves the repression
(Boyle et al., 1991; de Groot et al., 1993; Nikolakaki et al.,
1993; Aberle et al., 1997; Beals et al., 1997a,b; Diehl et al.,
1998; Graef et al., 1999). The list of putative substrates of
GSK-3 suggested that this kinase might also play a nega-
tive modulatory role in hypertrophy since it negatively
regulates the actions of major targets of two cytosolic sig-
naling pathways that have been implicated in the hyper-
trophic response to pressure overload in the intact animal.
These pathways, the calcineurin pathway and a pathway
culminating in activation of the stress-activated protein ki-
nases (SAPKs, also known as c-Jun NH
 
2
 
-terminal kinases
or JNKs), activate NF-ATs and c-Jun, respectively (Pul-
verer et al., 1991; Dérijard et al., 1994; Kyriakis et al., 1994;
Beals et al., 1997a).
Calcineurin, activated by calmodulin binding in the
presence of elevated cytosolic free [Ca
 
2
 
1
 
], dephosphory-
lates NF-ATs, exposing the nuclear localization signals
(Beals et al., 1997a; Crabtree, 1999; Zhu and McKeon,
1999). NF-ATs then translocate to the nucleus and acti-
vate transcription of a number of genes involved in a vari-
ety of responses, including the immune response (Rao et
al., 1997). When calcium levels return to normal and cal-
cineurin is inactivated, phosphorylation of NF-ATs leads
to their rapid export from the nucleus, terminating the sig-
nal (Zhu and McKeon, 1999). Although the role of NF-
ATs in the hypertrophic response of cardiomyocytes to
physiologically relevant stimuli is not clear, Molkentin et
al. (1998) were able to induce hypertrophy in transgenic
mice by expressing activated NF-ATc4. These data suggest
that calcineurin’s prohypertrophic effects are mediated, at
least in part, via activation of one or more NF-ATs. More
recently, calcineurin-induced activation of NF-ATc1 (NF-
AT2/c) was shown to play a role in skeletal myocyte hy-
pertrophy (Musaro et al., 1999).
GSK-3
 
b
 
 has been reported to regulate nuclear/cytoplas-
mic partitioning of various NF-ATs. GSK-3
 
b
 
 has been
shown to induce nuclear export of transfected NF-ATc1 in
COS cells, and of transfected NF-ATc4 (NF-AT3) in hip-
pocampal neurons (Beals et al., 1997b; Graef et al., 1999).
Although several other kinases also have been implicated
in regulation of NF-AT subcellular localization (Zhu et al.,
1998; Chow et al., 2000; Porter et al., 2000), these data
raise the possibility that GSK-3
 
b
 
 could exert an antihyper-
trophic effect in the heart by affecting nuclear/cytoplasmic
partitioning of endogenous NF-ATs in cardiac myocytes.
c-Jun, a major SAPK target (Pulverer et al., 1991; Kyri-
akis et al., 1994), is also negatively regulated by phosphor-
ylation by GSK-3 (Boyle et al., 1991; de Groot et al., 1993;
Nikolakaki et al., 1993). Phosphorylation reduces the
DNA binding activity of c-Jun, and thus the activity of AP-1
(a heterodimer of c-Jun and c-Fos family members). Since
the SAPKs recently have been shown to be necessary for
the hypertrophic response of neonatal cardiomyocytes to
endothelin-1 (ET-1) and for the development of pressure
overload-induced hypertrophy in the intact rat (Chouk-
roun et al., 1998, 1999), inhibition of activity of one of the
primary targets of the SAPKs, AP-1, could be another
 
mechanism whereby GSK-3 might negatively regulate hy-
pertrophy.
Herein, we explore the role of GSK-3
 
b
 
 in the hyper-
trophic response of cardiomyocytes. Our data indicate that
inhibition of GSK-3
 
b
 
 is a critical step in the development
of a cardiac hypertrophic response.
 
Materials and Methods
 
Materials 
 
Antibodies used were: anti-GSK-3
 
b
 
 mAb (Transduction Laboratories),
antiatrial natriuretic factor (anti-ANF; Peninsula Laboratories), anti-
 
a
 
-acti-
nin mAb (Sigma-Aldrich), rabbit anti-NF-ATc1 (K-18), which recognizes
all NF-AT family members (Santa Cruz Biotechnology), antiphospho Ser
9 GSK-3
 
b
 
 that specifically recognizes Ser 9 phosphorylated GSK-3
 
b
 
 (New
England Biolabs), and Cy3-conjugated anti-rabbit and anti-mouse anti-
bodies (BioRad). Other reagents included glycogen synthase peptide-2
(Upstate Biotechnology, Inc.), ET-1 and phenylephrine (PE; Sigma-
Aldrich), and insulin-like growth factor-1 (IGF-I; Calbiochem).
 
Cell Culture 
 
Spontaneously beating neonatal myocytes were prepared from 1–2-d-old
rats and cultured in F-10 medium in the presence of 5% FBS and 10%
horse serum as previously described (Choukroun et al., 1998).
 
Adenoviral Vectors 
 
Construction of Recombinant Adenoviral Vector Carrying the GSK-3
 
b
 
A9
cDNA.  
 
The cDNA encoding GSK-3
 
b
 
A9, carrying a Ser-to-Ala substitu-
tion at Ser 9 in the NH
 
2
 
-terminal region of GSK-3
 
b
 
, and an HA epitope
tag at the COOH terminus was created by PCR as described (Stambolic
and Woodgett, 1994). The cDNA was subcloned into the pAdTRACK-
CMV shuttle vector (obtained from B. Vogelstein, Johns Hopkins Univer-
sity, Baltimore, MD) that encodes green fluorescent protein (GFP) from
one CMV promoter and the gene of interest from a second CMV pro-
moter (He et al., 1998). AdGSK-3
 
b
 
A9, the recombinant adenovirus, was
prepared using the AdEASY system as described (He et al., 1998). The
recombinant virus was propagated in 293 cells and high titer stocks (
 
$
 
10
 
12
 
particles/ml) were purified by CsCl density gradient centrifugation.
 
Other Adenoviral Vectors.  
 
Ad
 
b
 
galEGFP (herein referred to as
AdGFP), carrying the 
 
Escherichia coli
 
 LacZ gene in addition to the GFP
gene, was used as a control virus. AdBD110, which encodes the 110-kD
catalytic subunit of phosphoinositide 3-kinase (PI3-K), rendered constitu-
tively active by including in-frame the p110-binding domain of human p85
(amino acids 474–552), has been previously described in detail (Matsui et
al., 1999). When cardiomyocytes are infected with AdBD110, they have
constitutively elevated levels of 3-phosphorylated phosphoinositides and
increased activity of PKB/Akt (Matsui et al., 1999). AdPKB/Akt, encod-
ing protein kinase B (PKB)/Akt made constitutively active by the addition
of a myristylation signal at the NH
 
2
 
 terminus of the kinase, was kindly
provided by Dr. Thomas Franke (Columbia University, New York, NY)
and has been described in detail (Matsui et al., 1999).
 
Cell Fractionation 
 
Cells were fractionated by hypotonic lysis. In brief, cells were suspended
in lysis buffer containing Hepes (20 mM, pH 7.5) and NaCl (10 mM) with
phosphatase and protease inhibitors. After 15 min on ice, lysates were
spun at 2,500 rpm for 5 min in an Eppendorf centrifuge. The pellet (nu-
clear fraction) was washed twice in lysis buffer, and then the supernatant
and pellet were spun at 14,000 rpm for 10 min. Protein concentrations of
the cytosolic and nuclear fractions were equalized, and then SDS sample
buffer was added to a final concentration of 1
 
3
 
.
 
Immunoblot Analysis 
 
For Western blot analysis, cell lysates were matched for protein concentra-
tion and were then separated by SDS-PAGE and transfered to Hybond-C
extra (Amersham Pharmacia Biotech). The membranes were blocked in
5% nonfat milk and then incubated with the indicated antibodies for 1 h at
room temperature. Antibody binding was detected with a peroxidase-con-
jugated goat anti–rabbit or anti–mouse IgG and chemiluminescence. 
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Immune Complex Kinase Assay of GSK-3
 
b 
 
For the studies of GSK-3
 
b
 
 activity in aortic banded hearts, the left ventri-
cle was pulverized under liquid nitrogen, homogenized with a polytron in
lysis buffer containing protease and phosphatase inhibitors (Pombo et al.,
1994; Choukroun et al., 1999), and then briefly sonicated. After 15 min on
ice with vortexing, the samples were centrifuged at 100,000 
 
g
 
 for 1 h at
4
 
8
 
C. Supernatants from heart lysates, or from lysates of neonatal cardio-
myocytes in culture, were matched for protein concentration, and were
incubated with anti-GSK-3
 
b
 
 mAb or anti-HA mAb for 2 h, and then com-
plexes were collected with protein G–Sepharose beads for an additional
1 h. Beads were washed six times in lysis buffer and three times in assay
buffer, and then were incubated for 20 min at 30
 
8
 
C with glycogen synthase
peptide-2 (50 
 
m
 
M) and 100 
 
m
 
M 
 
g
 
[
 
32
 
P]ATP (3,000–4,000 cpm/pmol) in the
presence of 10 mM MgCl
 
2
 
. Contents of the assays were spotted onto P81
phosphocellulose papers that were washed and then subjected to liquid
scintillation counting. Kinase activity was reduced to background levels
when 10 mM LiCl was included in the reaction mix, suggesting the activity
measured was GSK-3
 
b
 
 and not a contaminating kinase.
 
[
 
3
 
H]-leucine Incorporation 
 
Neonatal cardiomyocytes were infected with AdGSK-3
 
b
 
A9 or AdGFP in
F-10 medium containing 0.1% FCS. 36 h later, cells in triplicate wells of
12-well plates were stimulated with ET-1 (100 nM) for 36 h in serum-free
F-10 medium and then incubated in the same medium with 1.0 
 
m
 
Ci/ml
[
 
3
 
H]-leucine for an additional 12 h. The cells were processed as described
(Choukroun et al., 1998), and [
 
3
 
H]-leucine incorporation was determined
by liquid scintillation counting.
 
Immunocytochemistry 
 
Cardiomyocytes, grown on laminin-coated plastic coverslips, were in-
fected with either AdGFP or AdGSK-3
 
b
 
A9. 36 h later, they were exposed
to ET-1 or PE in serum free medium. For assessment of sarcomere organi-
zation and ANF expression, the cells were fixed 48 h later for 10 min with
4% parformaldehyde/5% sucrose in PBS. Coverslips were processed as
described (Molkentin et al., 1998). For sarcomere staining, coverslips were
incubated in a 1:400 dilution of anti–
 
a
 
-actinin mAb and for ANF staining
in a 1:400 dilution of anti-ANF antibody in blocking solution. Coverslips
were then incubated in a Cy3-conjugated secondary antibody diluted
1:800 in blocking solution for 1 h at room temperature. Cells were photo-
graphed using a Nikon FXA photomicroscope. Figures were prepared us-
ing Canvas 6.0.1 (Deneba Systems, Inc.) and were then transferred to
Adobe Photoshop 5.5 for printing.
 
Statistical Analysis 
 
Data are expressed and presented in the figures as mean 
 
6 
 
SEM. A 
 
t
 
 test
was used to compare the means of normally distributed continuous vari-
ables. A value of
 
 P 
 
, 
 
0.05 was chosen as the limit of statistical significance.
 
Results
 
GSK-3
 
b
 
 Is Inhibited by Hypertrophic Stimuli 
 
If GSK-3
 
b
 
 plays an important role in the hypertrophic re-
sponse, its activity should be inhibited by hypertrophic
stimuli. Therefore, we exposed neonatal rat cardiomyo-
cytes to ET-1 or, as a positive control, IGF-1, another hy-
pertrophic agent known to inhibit GSK-3
 
b
 
. Cell lysates
were prepared and subjected to immunoprecipitation with
an anti-GSK-3
 
b
 
 antibody, followed by assay with the gly-
cogen synthase-2 peptide as substrate. IGF-1 produced a
45% decrease in GSK-3
 
b
 
 activity, consistent with prior ob-
servations using insulin in various cell lines (Cross et al.,
1995; Moule et al., 1997). In response to ET-1 (100 nM),
GSK-3
 
b
 
 was inhibited by as much as 60% at 40 min.
Thereafter, GSK-3
 
b
 
 activity returned toward control lev-
els, but some inhibition persisted for at least 90 min (Fig. 1
A). Inhibition with PE (20–30%) was not as marked as
with ET-1, but was significant (data not shown). Although
PE-induced inhibition is less than the inhibition seen with
IGF-1, this percent inhibition is equivalent to that seen
with NGF and HGF (20–30% inhibition), and this degree
of inhibition is believed to play an important role in the
antiapoptotic effect of NGF in PC12 cells (Pap and Coo-
per, 1998) and in the HGF-induced accumulation of 
 
b
 
-cat-
enin in mouse mammary epithelial cells (Papkoff and
Figure 1. Inhibition of GSK-3b by ET-1 in neonatal cardiomyo-
cytes in culture (A), and by pressure overload in vivo (B). A,
Cardiomyocytes were exposed to IGF-1 (40 ng/ml) for 20 min, or
to vehicle or ET-1 (100 nM) for 20, 40, 60, or 90 min, followed by
immune complex kinase assays for GSK-3b activity. Percent inhi-
bition of GSK-3b activity is expressed relative to vehicle controls.
Western blot of total GSK-3b in the lysates is shown below the
graph. n 5 3 experiments, assayed in duplicate. *P , 0.01 vs. ve-
hicle control. B, Rats were subjected to aortic banding or sham
banding, and then were killed at 2, 4, 24, or 48 h after banding.
GSK-3b immune complex kinase assays were performedon myo-
cardial lysates, and percent inhibition of kinase activity is ex-
pressed relative to sham banded animals. n 5 3 animals per con-
dition. *P , 0.01 vs. sham banded animals. 
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Aikawa, 1998). These data suggest that the degree of inhi-
bition of GSK-3
 
b
 
 by ET-1 and PE in cardiomyocytes is
sufficient to have potentially important biological effects.
To determine whether GSK-3
 
b
 
 might play a role in the
hypertrophic response to a physiologically relevant stimu-
lus in vivo, rats were subjected to aortic banding or sham
banding as described (Choukroun et al., 1999), and GSK-
3
 
b
 
 immune complex kinase assays were performed on
myocardial lysates at various times after banding. We found
that GSK-3
 
b
 
 activity was significantly reduced in response
to pressure overload and inhibition persisted for 24 h (Fig.
1 B). Taken together, these data are consistent with a pos-
sible role for GSK-3
 
b
 
 in the hypertrophic response of car-
diomyocytes in culture and in pressure overload-induced
hypertrophy in vivo.
 
Mechanism of Inhibition of GSK-3
 
b
 
 by
Hypertrophic Stimuli 
 
Several mechanisms of inhibition of GSK-3 have been de-
scribed. Insulin and IGF-1 inactivate GSK-3 via phosphor-
ylation of a serine residue in the NH
 
2
 
-terminal region of
the kinase (Ser 9 for GSK-3
 
b
 
 and Ser 21 for GSK-3
 
a
 
;
Stambolic and Woodgett, 1994). This is mediated by a PI3-
K-dependent kinase, possibly either PKB/Akt or the inte-
grin-linked kinase (ILK; Cross et al., 1995; Delcommenne
et al., 1998). Other mechanisms, including one mediated
by Ca
 
2
 
1
 
 and a Ca
 
2
 
1
 
/calmodulin-dependent protein kinase
kinase (Yano et al., 1998), and an ill-defined mechanism
employed by the Wnt/wingless pathway, possibly involv-
ing protein kinase C (Cook et al., 1996), also inactivate
GSK-3, but these pathways are not PI3-K-dependent and
do not result in phosphorylation of Ser 9. Therefore, we
determined the mechanism of inhibition of GSK-3
 
b
 
 by hy-
pertrophic stimuli. We found that ET-1 induced pro-
nounced phosphorylation of GSK-3
 
b
 
 on Ser 9, and that
this phosphorylation was blocked by the PI3-K inhibitors,
wortmannin or LY294002 (Fig. 2 A). The effect of the PI3-K
inhibition on Ser 9 phosphorylation exactly correlated
with the effect on GSK-3
 
b
 
 kinase activity, since wort-
mannin prevented the ET-1–induced inactivation of
GSK-3
 
b
 
 (Fig. 2 B). These data strongly suggest that the
ET-1–induced inhibition of GSK-3
 
b
 
 is mediated via phos-
phorylation of Ser 9 by a PI3-K-dependent kinase.
To confirm that phosphorylation of Ser 9 was the mecha-
nism of inactivation of GSK-3
 
b
 
, we created an adenovirus
encoding GSK-3
 
b
 
 with a Ser 9 to Ala mutation that renders
the kinase resistant to inhibition by Ser 9 kinases, and then
determined whether GSK-3
 
b
 
A9 was inhibited in response
to ET-1. Cells were transduced with AdGSK-3
 
b
 
A9,
AdGFP (as a control), or no virus. 36 h later, cells were ex-
posed to ET-1 for 40 min, followed by immunoprecipitation
 
Figure 2.
 
Hypertrophic stimuli inhibit GSK-3
 
b
 
 via phosphoryla-
tion of Ser 9 by a PI3-K-dependent protein kinase. A, ET-1 in-
duces Ser 9 phosphorylation of GSK-3
 
b
 
 by a PI3-K–dependent
kinase. Cells were pretreated for 30 min with vehicle (DMSO),
wortmannin (100 nM), or LY294002 (10 
 
m
 
M), and then were
stimulated with vehicle (ET
 
2
 
) or ET-1 (ET
 
1
 
) for 40 min. West-
ern blotting of whole cell lysates was performed with antiphos-
pho Ser 9 GSK-3
 
b
 
 and, to confirm that equivalent amounts of
protein were loaded, with anti-GSK-3
 
b
 
. Experiment shown is
representative of three. B, ET-1–induced inactivation of GSK-3b
is PI3-K-dependent. Cardiomyocytes were pretreated for 30 min
with wortmannin (100 nM) or vehicle (DMSO), and then were
stimulated with ET-1 or vehicle for 40 min, followed by GSK-3b
immune complex kinase assay. n 5 3 experiments, assayed in du-
plicate. *P , 0.01 vs. control (ET2/WT2). #P , 0.01 vs. ET-1
alone (ET1/WT2). C, GSK-3bA9 is not inhibited by ET-1 in
cardiomyocytes. Cells were transduced with AdGSK-3bA9 (A9)
or AdGFP (GFP) at an MOI of 100 pfu/cell, or no virus (C). 36
hours later, cells were stimulated with vehicle or ET-1 for 30 min,
lysates were prepared and anti-HA immune complex kinase as-
says were performed. Experiments were performed in parallel
with the experiments presented in Fig. 1 A, demonstrating signif-
icant inhibition of GSK-3b by ET-1. *P , 0.01 vs. respective no
virus control (C) and GFP virus control. Haq et al. GSK-3 and Cardiac Hypertrophy 121
with anti-HA mAb and immune complex kinase assay. In
contrast to endogenous GSK-3b (Figs. 1 A and 2 B), GSK-
3bA9 was not inhibited by ET-1 (Fig. 2 C). These data con-
firmed a critical role for Ser 9 phosphorylation in the
ET-1–induced inactivation of GSK-3b. In addition, they
demonstrated that we could employ the virus to study the
role of GSK-3 inhibition in the hypertrophic response to
ET-1.
Inhibitors of GSK-3 Induce Hypertrophic Responses in 
Cardiac Myocytes 
If the ET-1–induced inhibition of GSK-3 were mediated
by activation of the PI3-K/PKB pathway, and if this inhibi-
tion were important in the hypertrophic response, then di-
rectly activating the PI3-K/PKB pathway should induce
hypertrophic responses. To initially explore this question,
we induced inhibition of GSK-3 by adenovirus-mediated
gene transfer of either the constitutively active mutant of
PKB/Akt (AdPKB/Akt), or the constitutively active PI3-
K (AdBD110), which produces persistent activation of en-
dogenous PKB/Akt (Matsui et al., 1999), and determined
their effects on protein accumulation in neonatal myo-
cytes. Adenoviral gene transfer of either BD110 or acti-
vated PKB/Akt significantly increased protein accumula-
tion, demonstrating that activation of the PI3-kinase/Akt
pathway is sufficient to induce hypertrophic responses
(Fig. 3). In addition, we employed LiCl, which has been
used to directly inhibit GSK-3 in many contexts (see be-
low). Even in the absence of a hypertrophic stimulus, LiCl
was sufficient to induce protein accumulation in cardiac
myocytes (Fig. 3). Whereas BD110, PKB/Akt, and LiCl
have effects in cells in addition to inhibiting GSK-3, the
data are consistent with a possible role for the PI3-K/Akt/
GSK-3 pathway in the hypertrophic response.
Expression of GSK-3bA9 Blocks the Hypertrophic 
Response to ET-1 and PE
Expression of GSK-3bA9.  To address our primary ques-
tion, whether inactivation of GSK-3b is necessary for the
hypertrophic response to physiologically relevant stimuli,
we expressed GSK-3bA9 in neonatal cardiomyocytes via
adenoviral gene transfer and determined its effect on the
hypertrophic response. GSK-3bA9 was readily expressed
in culture using multiplicities of infection (MOIs) of 50–
125 pfu/cell. At an MOI of 100 pfu/cell, expression levels
of GSK-3bA9 were only slightly greater than levels of en-
dogenous GSK-3b (Fig. 4), and transduction efficiency
was  z85% (not shown). It is important to note that the ex-
pression levels that we achieved at an MOI of 100 pfu/cell
did not produce marked elevations in total cellular GSK-
3b activity. When we measured total GSK-3b activity in
cells infected with AdGSK-3bA9, activity was increased
only 1.8 6 0.2-fold over cells infected with control virus
(AdGFP). This level of activity is in distinct contrast to ac-
tivity levels seen after gene transfer or transfection of con-
stitutively active kinases that are normally off in the rest-
ing cell. In these cells, total kinase activity is often many
fold greater than endogenous activity.
Effect of GSK-3bA9 on Hypertrophic Responses. If in-
hibition of GSK-3b is important in the hypertrophic
response of cardiomyocytes, preventing inactivation of
GSK-3 should block the hypertrophic response. There-
fore, we determined whether gene transfer of GSK-3bA9
blocked the hypertrophic response to ET-1 and PE. For
these studies, we took advantage of the fact that we made
AdGSK-3bA9 with the pAdTRACK/pAdEASY system
(He et al., 1998), which allows expression of GFP from a
separate promoter in the virus. We identified transduced
cells by their green fluorescence, and could then compare
hypertrophic responses in cells that were successfully
transduced with those that were not transduced. To sum-
marize the data presented below, we found that expres-
sion of GSK-3bA9 significantly inhibited ET-1– and PE-
induced hypertrophy and, importantly, that LiCl, which
inhibits endogenous GSK-3 and GSK-3bA9, reversed the
effects of gene transfer of GSK-3bA9.
Enhanced organization of sarcomeres, which character-
izes the hypertrophic response of neonatal cardiomyo-
cytes, was markedly inhibited by expression of GSK-3bA9
(Fig. 5, a and b). However, in myocytes expressing GSK-
3bA9 that were also treated with LiCl (10 mM), ET-1– and
Figure 3. Gene transfer of constitutively active PI3-K (BD110) or
PKB/Akt, or treatment with LiCl induces protein synthesis in neo-
natal rat cardiomyocytes. Neonatal cardiomyocytes were treated
with vehicle (Control), ET-1, or LiCl for 48 h (left side), or were
transduced with AdBD110 or AdPKB/Akt, or with control virus
(AdGFP) for 48 h. Leucine incorporation was determined over the
last 12 h of the incubation. *P , 0.01 vs. vehicle control. #P , 0.01
vs. virus control (GFP).
Figure 4. Expression of GSK-3bA9 in neonatal cardiomyocytes.
Neonatal myocytes were transduced with AdGFP (GFP) or
AdGSK-3bA9 (A9) at an MOI of 100. 36 h later, cell lysates were
prepared, and Western blotting with anti-GSK-3b mAb was per-
formed. Due to the HA tag, GSK-3bA9 runs at a slightly higher
Mr than does the endogenous kinase. Of note, LiCl did not affect
expression of GSK-3bA9 (data not shown).The Journal of Cell Biology, Volume 151, 2000 122
Figure 5. Expression of GSK-3bA9 inhibits ET-1– and PE-induced sarcomere organization. a, Cells were transduced with AdGFP or
AdGSK-3bA9, or no virus (Control). 36 h later, cells were treated with vehicle, ET-1, or PE, with or without LiCl present. Sarcomere orga-
nization was determined 48 h later. Expression of GSK-3bA9, as opposed to expression of GFP, markedly reduces ET-1– and PE-induced
sarcomere organization (compare H with E, and I with F), and this effect of GSK-3bA9 is reversed by LiCl (10 mM; compare K with H, and
L with I). M shows the moderate sarcomere organization that is induced by 48 h of LiCl in the absence of ET-1. b, Quantitation of sarco-
mere organization. Cardiomyocytes, which had been transduced with AdGFP or AdGSK-3bA9 (A9), were treated with vehicle (C), ET-1,
or PE, in the presence or absence of LiCl (10 mM) (A9/Li). 48 h later, myocytes (n $ 100 per experiment, n 5 3 experiments) were scored
for the presence or absence of highly organized sarcomeres. *P , 0.01 vs. control/GFP. #P , 0.01 vs. respective GFP and A9/Li conditions.Haq et al. GSK-3 and Cardiac Hypertrophy 123
PE-induced sarcomere organization was restored (Fig. 5, a
and b). Of note, treatment of myocytes with LiCl alone, in
the absence of ET-1 or PE, induced only moderate sarco-
mere organization (Fig. 5 a), suggesting that inhibition of
GSK-3b is necessary, but is not sufficient for the full ex-
pression of this relatively complex component of the hy-
pertrophic response that requires the coordinate expres-
sion of a number of genes.
Next we examined the role of the GSK-3b pathway in
the induction of ANF, one of the marker genes that is up-
regulated in response to most hypertrophic stimuli. We
found that ET-1 induced expression of ANF (Fig. 6 a), but
that gene transfer of GSK-3bA9 markedly inhibited the
ET-1–induced expression of ANF (Fig. 6, b, c, and d).
Again, LiCl completely reversed the effects of expression
of GSK-3bA9. Although LiCl alone was not sufficient to
induce full sarcomere organization (Fig. 5 a), LiCl was suf-
ficient, even in the presence of GSK-3bA9, to induce ANF
expression, suggesting that inhibition of GSK-3b is not
only necessary, but may also be sufficient for this compo-
nent of the response (Fig. 6, b, c, and d).
To determine whether inhibition of GSK-3b is necessary
for the enhanced protein accumulation that is characteris-
tic of the hypertrophic response, we measured ET-1–induced
[3H]-leucine incorporation in cells transduced with AdGSK-
3bA9. Expression of GSK-3bA9 significantly reduced ET-
1–induced [3H]-leucine incorporation (Fig. 7).
Mechanisms of Action of GSK-3b 
The hypertrophic response is an enormously complex re-
sponse that is regulated by multiple transcription factors
acting on multiple genes. This complexity makes it difficult
to identify critical roles for individual transcription factors.
However, several lines of evidence, in addition to the find-
ings described above with the transgenic mouse expressing
an activated mutant of NF-ATc4, suggest NF-ATs play a
role in the response. In neonatal rat cardiomyocytes in cul-
ture, cyclosporin A blocks ANF induction by angiotensin
II and PE (Molkentin et al., 1998), and by ET-1 (data not
shown). These data confirm that calcineurin is critical to
this component of the response and are compatible with a
role for one or more NF-ATs in ANF induction. Further-
more, adenovirus-mediated gene transfer of activated NF-
ATc4 (NF-ATc4D317; Molkentin et al., 1998), in the ab-
sence of hypertrophic stimuli, induces ANF expression
and sarcomere organization (data not shown).
We found that ET-1 induced marked nuclear transloca-
tion of an endogenous NF-AT of molecular mass z95 kD
(Fig. 8 A). Specific antibodies to the various NF-ATs are
not adequate for use in the rat. However, of the three NF-
ATs expressed in the heart, NF-ATc1 (NF-ATc), NF-
ATc3 (NF-AT4/x), and NF-ATc4 (NF-AT3; J. Molkentin,
manuscript in preparation), this molecular mass is most
compatible with NF-ATc1. NF-AT first appeared in the
nucleus at z30 min after ET-1 (Fig. 8 A), corresponding to
the time of maximal inhibition of GSK-3b activity (Fig. 1
A). Nuclear NF-AT levels declined after 120 min, a time
when GSK-3b activity was returning toward normal (Fig. 8
A). Thus, the time courses of endogenous NF-AT nuclear
localization and GSK-3b activity are compatible with a
role for GSK-3b in regulating nuclear/cytoplasmic parti-
tioning of NF-AT.
Prior studies examining the role of GSK-3b in the nu-
clear export of NF-ATs have employed overexpression of
GSK-3b. In these studies, GSK-3b is found in the nucleus
and induces export of NF-ATs (Beals et al., 1997b; Graef
et al., 1999). However, it is not clear whether endogenous
GSK-3b also translocates to the nucleus in a stimulus-
dependent manner. We found that in the unstimulated car-
diomyocyte, little GSK-3b is nuclear localized (Fig. 8 B).
ET-1 induced a pronounced translocation of GSK-3b to
the nucleus (Fig. 8 B). This translocation was evident as
early as 30 min and persisted until after 90 min. These data
confirm that endogenous GSK-3b translocates to the nu-
cleus in response to hypertrophic stimuli, colocalizing with
its putative target, NF-AT.
Thus, the time courses of GSK-3b activity and nuclear
localization, and the time course of NF-AT nuclear local-
ization, were consistent with a role for GSK-3b in regulat-
ing NF-AT nuclear/cytoplasmic partitioning, following hy-
pertrophic stimuli. To directly address whether GSK-3b
modulated NF-AT activity in response to hypertrophic
stimuli, we examined the effects of expressing GSK-3bA9
on the nuclear/cytoplasmic partitioning of NF-AT in car-
diomyocytes exposed to ET-1. As noted above, NF-AT first
appeared in the nucleus at z30 min after ET-1 in control
(Fig. 8 A) and AdGFP-infected cells (Fig. 8 C). Expression
of GSK-3bA9 significantly delayed the appearance of NF-
AT in the nucleus, compatible with retardation of entry by
cytosolic GSK-3b (Fig. 8 C). By 60 min, however, the
amount of intranuclear NF-AT was equivalent in cells in-
fected with AdGSK-3bA9 and AdGFP (Fig. 8 C), suggest-
ing the inhibitory effect of GSK-3bA9 was overcome by
activated calcineurin. A significant fraction of the NF-AT
remained intranuclear at 120 min after ET-1 in control
(Fig. 8 A) and AdGFP-infected cells (Fig. 8 C), but ex-
pression of GSK-3bA9 accelerated its export from the nu-
cleus such that little remained intranuclear at 120 min (Fig.
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Figure 6. Expression of GSK-3bA9 inhibits ET-1–induced ANF expression. A, ET-1 induces ANF expression in cardiomyocytes. Myo-
cytes were treated with vehicle or ET-1, and 48 h later were stained for ANF expression. Two vehicle-treated cells were positive for ANF
expression whereas the majority of ET-1–treated cells were positive. B, Effect of GSK-3bA9 on ANF expression. Cardiomyocytes were
transduced with either AdGFP or AdGSK-3bA9 (MOI 5 50 pfu/cell), and then were exposed to ET-1 with or without LiCl present. The
left panels show staining for ANF expression and the right panels show GFP expression, thus identifying the cells in each field that were
successfully transduced with the virus. The control virus (AdGFP) does not prevent ET-1–induced ANF expression (A and B). For the
cells transduced with AdGSK-3bA9, in the absence of LiCl (C and D), of the seven cells expressing ANF, none were transduced with
AdGSK-3bA9 (compare C and D). In contrast, none of the cells that were transduced with AdGSK-3bA9 (green) express ANF. How-
ever, numerous cells transduced with AdGSK-3bA9 express ANF when LiCl is present (E and F), and LiCl restores ET-1 responsiveness
in GSK-3bA9-expressing cells (G and H). C, Quantitation of the effect of GSK-3bA9 on ANF expression. Cells were transduced with
AdGFP (GFP), or AdGSK-3bA9 (A9), and then were exposed to ET-1 or vehicle, with or without LiCl present (A9/Li). The percent of
transduced cells (i.e., GFP positive) expressing ANF was then determined for the various conditions. Also shown is ANF expression in
control cells not transduced with virus (C). At least 100 myocytes were scored for each experiment. *P , 0.01 vs. vehicle-treated control
cells (C/ET2), GFP infected cells (GFP/ET2), and A9 infected cells (A9/ET2). #P , 0.01 vs. all ET-1–treated cells. D, Immunoblot con-
firming the findings from B and C. Cardiomyocytes were infected with AdGSK-3bA9 (A9) (MOI 5 100 pfu/cell) or no virus (C), and then
were exposed to vehicle or ET-1, with or without LiCl present. Expression of GSK-3bA9 prevented ET-1–induced ANF expression, and
LiCl reversed the inhibition. Also shown is the effect of LiCl alone, which induces moderate ANF expression. Below the immunoblot is a
graph showing quantitation of ANF expression by band densitometry from n 5 3 experiments. *P , 0.05 vs. C, A9/Control, and A9/ET.Haq et al. GSK-3 and Cardiac Hypertrophy 125
8 C). Thus, expression of GSK-3bA9 significantly reduced
the duration of NF-AT nuclear localization, both by re-
tarding entry into and enhancing exit from the nucleus.
These data suggest GSK-3b modulates the hypertrophic
response of cardiac myocytes in part by regulating the nu-
clear/cytoplasmic partitioning of NF-AT.
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Discussion
In this manuscript, we identify a novel function of GSK-
3b. We demonstrate that GSK-3b plays a critical role in
the hypertrophic response of cardiomyocytes by showing
that GSK-3b kinase activity is inhibited by hypertrophic
stimuli both in vitro and in vivo, and that inhibition of
GSK-3b activity is essential for all three components of
the hypertrophic response of cardiomyocytes enhanced
protein accumulation and sarcomere organization, and re-
expression of fetal genes. Furthermore, we show that
GSK-3b likely limits the hypertrophic response, at least in
part, by negatively regulating ET-1–induced nuclear local-
ization of NF-AT.
Numerous signaling molecules have been identified,
which, when activated, transduce prohypertrophic signals,
and some, such as the SAPK/JNKs, calcineurin, and the a
subunit of Gq heterotrimeric G proteins, have been shown
to be essential for the development of cardiac hypertrophy
in vivo to physiologically relevant stimuli (reviewed in
Force et al., 1999a,b; Olson and Molkentin, 1999; Sugden,
1999). To date, few studies have identified pathways that
negatively regulate the hypertrophic response, yet these
may be equally attractive targets for therapies designed to
block the progression of hypertrophy and the transition to
heart failure.
GSK-3 is normally active in unstimulated cells, and is in-
activated in response to growth factors, especially insulin
and IGF-1, which activate the PI3-K pathway (Avruch,
1998). We now demonstrate that GSK-3b is potently in-
hibited by hypertrophic agonists with receptors coupled to
heterotrimeric G proteins of the Gq class. Morisco et al.
(2000) recently showed that stimulation of b-adrenergic
receptors, which are coupled to Gs proteins, also inhibited
GSK-3b, suggesting that inhibition of this kinase may be a
generalized phenomenon of hypertrophic signaling in cells
in culture. We also showed that GSK-3b is markedly in-
hibited in the intact animal exposed to pressure overload
induced by aortic banding, a stress that mimics severe val-
vular or hypertensive disease.
Recently, Rezvani and Liew (2000) reported that human
hypertrophy is associated with elevated levels of b-catenin
protein, a transcriptional activator involved in embryonic
development and tumorigenesis, not previously known to
play a role in hypertrophy. Since GSK-3b, when active,
phosphorylates b-catenin, targeting it for ubiquitination
and degradation, inhibition of GSK-3b may account, in
part, for the increased expression of b-catenin. We believe
b-catenin may be an additional target of GSK-3b that is
involved in the hypertrophic response and studies evaluat-
ing this hypothesis are in progress.
GSK-3b activity can be inhibited by a number of mecha-
nisms, but our findings suggest that hypertrophic agonists
utilize phosphorylation of Ser 9 by a PI3-K–dependent
protein kinase. This phosphorylation can be catalyzed by
at least two protein kinases, PKB/Akt and ILK, both of
which are activated by phosphatidylinositol 3 phosphates
(Coffer et al., 1998; Delcommenne et al., 1998). It is un-
clear which of the two is the physiologically relevant ki-
nase that inactivates GSK-3 in response to hypertrophic
stimuli. The data confirm that the inhibition of GSK-3b is
not mediated via recruitment of the Wnt pathway by hy-
pertrophic agonists since Wnt-induced inhibition of GSK-
3b appears to be PI3-K-independent (Cook et al., 1996).
Ultimately, cytosolic signaling pathways must modulate
the activity of various transcription factors to direct the
complex reprogramming of gene expression required to ex-
press the full hypertrophic phenotype. Our data suggest
that one critical target of GSK-3 that likely plays a role in
the hypertrophic response of cardiac myocytes is a member
of the NF-AT family of transcription factors. NF-AT family
members have been implicated in both cardiac hypertrophy
and IGF-1–induced skeletal myocyte hypertrophy (Mol-
kentin et al., 1998; Musaro et al., 1999). NF-AT activity is
largely controlled at the level of nuclear localization since
the cytoplasmic forms are competent for both DNA bind-
ing and transcriptional activation (Beals et al., 1997a,b).
NF-ATs appear to be held in the cytoplasm by the masking
of two nuclear localization signals by the intramolecular in-
teraction of several phosphorylated serine residues with a
second serine-rich region (Crabtree, 1999). Dephosphoryla-
tion of the serine residues by calcineurin exposes the nu-
clear localization signals leading to nuclear import.
Several protein kinases in addition to GSK-3b have been
implicated in the nuclear export and/or cytosolic anchoring
of NF-AT family members. Three MAP kinases (SAPKs,
ERKs, and p38), protein kinase A, casein kinase Ia in co-
operation with MAP kinase/ERK kinase-1, and casein ki-
nase 2 have been reported to phosphorylate critical resi-
dues in the SerPro-rich domain of one or more NF-ATs,
blocking nuclear import and/or enhancing export (Zhu et
al., 1998; Chow et al., 2000; Porter et al., 2000). The role of
these kinases has been examined primarily in T cells, hip-
pocampal neurons, or transformed cell lines commonly
Figure 7. Effect of GSK-3bA9 on ET-1–induced protein synthe-
sis. Neonatal cardiomyocytes were transduced at an MOI of 125
pfu/cell with AdGSK-3bA9 or AdGFP for 36 h, or no virus (C),
and then were treated with ET-1 (1) or vehicle (2), with or with-
out LiCl present. [3H]-leucine incorporation was determined 48 h
later. n 5 6 experiments, each condition assayed in triplicate. *P ,
0.01 vs. respective vehicle control. #P , 0.01 vs. A9/ET-1.Haq et al. GSK-3 and Cardiac Hypertrophy 127
used in studies using transfection (e.g., COS cells), and few
studies have focused on the regulation of endogenous NF-
ATs. It appears from these studies that the relevant ki-
nase(s) regulating NF-AT nuclear/cytosolic partitioning
depends on the NF-AT, the cell type, and, possibly, the
stimulus. For our purposes, Beals et al. (1997b) have
clearly shown that GSK-3 regulates nuclear export of NF-
ATc1, the NF-AT we believe to be most highly expressed
in neonatal cardiomyocytes. More recently, Porter et al.
(2000) proposed that casein kinase 2, which is constitu-
tively nuclear localized, may serve as a priming kinase that
phosphorylates residues of NF-ATc1, allowing more effi-
cient phosphorylation by GSK-3b. They noted however,
that GSK-3b could, itself, also serve as the priming kinase.
Although the role of the other putative NF-AT kinases
in cardiomyocytes is not clear, out data confirm a critical
role for GSK-3b. We found that expression of GSK-3bA9
delayed the initial ET-1–induced import of NF-AT into
the nucleus, and, subsequently, enhanced nuclear export,
resulting in a markedly reduced duration of NF-AT nu-
clear localization. These data are compatible with an im-
portant role for GSK-3b in nuclear/cytoplasmic partition-
ing of NF-AT after stimulation by hypertrophic agonists.
In addition, we found that treatment of cells with LiCl in
the absence of ET-1 induced marked translocation of NF-
AT to the nucleus (data not shown), suggesting that GSK-
3b may not only retard stimulus-induced entry of NF-AT
into the nucleus, but also may be the dominant mechanism
for maintaining NF-AT in the cytosol in the unstimulated
or resting cardiac myocyte.
An alternative approach to studying the role of GSK-3b
(and NF-ATs) in the hypertrophic response would be to
Figure 8. Effect of GSK-3bA9
on ET-1–induced nuclear trans-
location of NF-AT. A, ET-1 in-
duces nuclear translocation of
NF-AT. Cardiomyocytes were
stimulated with ET-1 for the
times noted. Cytosolic and nu-
clear fractions were prepared,
matched for protein, and immu-
noblotted with anti–NF-AT anti-
body. This and all other immu-
noblots shown in this figure are
representative of three experi-
ments. B, ET-1 induces nuclear
translocation of GSK-3b. Cells
were stimulated with ET-1 for
the times noted and then were
subjected to cell fractionation.
Nuclear fractions were matched
for protein, and immunoblotted
with anti–GSK-3b. C, Expres-
sion of GSK-3bA9 reduces ET-
1–induced nuclear translocation
of NF-AT. Cardiomyocytes were
infected with AdGFP (top), or
AdGSK-3bA9 (bottom), and 36 h
later were stimulated with ET-1
for the times noted. Cytosolic
and nuclear fractions were
matched for protein, and immu-
noblotted with anti–NF-AT anti-
body. Below the immunoblots is
a graph showing quantitation of
NF-AT cytosolic and nuclear lo-
calization by band densitometry
from n 5 3 experiments. Each
value is normalized to the re-
spective cytosolic band density
at 0 min. *P , 0.05 for AdGSK-
3bA9 infected cells vs. AdGFP
infected cells.The Journal of Cell Biology, Volume 151, 2000 128
create mice deleted for one or more of these genes. How-
ever, the GSK-3b deletion is embryonic lethal. Fur-
thermore, the molecular mass of the dominant NF-AT
in neonatal rat cardiomyocytes is most compatible with
NF-ATc1, and mouse embryos lacking NF-ATc1 die at
day 11 from congestive heart failure due to improper for-
mation of the cardiac valves (Ranger et al., 1998). Mice de-
leted for the other NF-ATs expressed in the heart are via-
ble, but since cardiac myocytes contain more than one
NF-AT, deletion of one may be compensated for by the
others. Cross-breeding viable knockouts could clarify the
role of the NF-ATs in hypertrophy, but increases the prob-
ability of embryonic lethality.
Although we believe NF-ATs are important in the hy-
pertrophic response, several pieces of evidence suggest
that inhibition of NF-ATs is not the only mechanism by
which GSK-3 attenuates the hypertrophic response. For
example, in contrast to the marked hypertrophy seen
when an activated mutant of NF-ATc4, NF-ATc4D317, is
expressed in the hearts of transgenic mice (Molkentin et
al., 1998), expression of NF-ATc4D317 in neonatal rat car-
diomyocytes in culture induces a definite, but modest hy-
pertrophic response. Therefore, either NF-ATs are neces-
sary, but not sufficient for the full expression of the
hypertrophic phenotype, or, more likely, there are addi-
tional targets activated by ET-1 and PE (and inhibited by
GSK-3b) that play a role in the hypertrophic response. In
support of the latter possibility, preliminary experiments
suggest that expression of NF-ATc4D317 partially, but not
completely, overcomes the inhibitory effect of GSK-3bA9
on the hypertrophic response. In this regard, GSK-3 has
another target, c-Jun, which has been implicated in the hy-
pertrophic response. c-Jun was the first transcription fac-
tor identified as a substrate of GSK-3 (de Groot et al.,
1993; Nikolakaki et al., 1993). GSK-3 phosphorylates sev-
eral residues near the DNA binding domain of c-Jun, and
this negatively regulates the DNA binding activity of the
transcription factor. We have previously shown that the
SAPKs/JNKs, which increase the transcriptional activating
activity of c-Jun, are necessary for the hypertrophic re-
sponse of cardiomyocytes both in vitro and in vivo
(Choukroun et al., 1998, 1999), and, given the number of
hypertrophic response genes that appear to be regulated,
at least in part, by AP-1, a heterodimer of c-Jun and c-Fos
(reviewed in Olson and Molkentin, 1999), it is likely that
c-Jun plays an important role in hypertrophy. Therefore,
inhibition of c-Jun and, as a result, AP-1, may be a mecha-
nism in addition to inhibition of NF-ATs, whereby GSK-3
signals to blunt the hypertrophic response. In addition to
the effects of AP-1 itself on gene expression, AP-1 is also
required for efficient binding of NF-ATs to DNA (Rao et
al., 1997), suggesting an additional mechanism whereby
GSK-3b, via inactivation of AP-1, could block NF-AT–
dependent gene expression.
We employed LiCl to inhibit activity of GSK-3bA9 and
endogenous GSK-3. LiCl has been employed to this end to
study the role of GSK-3 in embryonic development in or-
ganisms as diverse as Dictyostelium, Xenopus laevis, sea
urchins, and zebrafish, and to study numerous processes in
mammalian cells (Klein and Melton, 1996; Stambolic et
al., 1996; Yamamoto et al., 1999). LiCl has no known ef-
fects on other protein kinases, but does have effects on
other enzymes, including inhibiting the inositol mono-
phosphatase and adenylyl cyclase. Whereas LiCl may have
other less well-described ancillary effects, the direct rever-
sal by LiCl of the effects of GSK-3bA9 on sarcomere orga-
nization, ANF expression, and protein synthesis suggests
Li1 mediated its actions primarily via inhibition of GSK-3.
An alternative strategy would have been to use kinase-in-
active GSK-3b. In our hands and others, kinase-inactive
GSK-3b is not an adequate dominant inhibitory mutant in
mammalian cells (Yuan et al., 1999), and needs to be ex-
pressed at high levels to function as an inhibitor of GSK-3
signaling. This may lead to nonspecific effects and requires
infection at high MOIs that can be toxic to cardiac myo-
cytes. Whereas this might not adversely affect activity of
reporter constructs (Morisco et al., 2000), it does disrupt
the complex and highly coordinated responses required to
produce the hypertrophic phenotype.
In summary, we have identified a novel role for GSK-3
as a critical negative modulator of cardiomyocyte hyper-
trophy. Our data suggest a model whereby GSK-3 directly
antagonizes the prohypertrophic effects of activated cal-
cineurin by inhibiting activity of one of its primary targets,
NF-AT. The elucidation of a central role for GSK-3 in hy-
pertrophy identifies not only GSK-3 and its downstream
effectors, but also a large number of signaling molecules
upstream of GSK-3, including PI3-Ks, polyphosphatidyl-
inositide-dependent protein kinases (PDKs), PKB/Akt,
and ILK, as potential therapeutic targets for drugs to alter
the natural history of hypertrophy and heart failure.
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